InvestorsHub Logo
Followers 42
Posts 8767
Boards Moderated 0
Alias Born 10/04/2017

Re: None

Tuesday, 01/09/2018 4:32:35 PM

Tuesday, January 09, 2018 4:32:35 PM

Post# of 12427
Lexington’s President Eric Willis comments, “After nine months of concerted effort by our design and production team, the arrival of our first human-use HeartSentry devices allows us to accelerate our plans to move ahead with our pilot study. Diablo Clinical Research is a proven and respected establishment with the capability to launch our research program efficiently and cost-effectively. They have been extremely helpful in the determination process which has led to today’s announcement. We are excited to begin this next step of our development phase, and look forward to sharing quantifiable results in the near future.

http://techstockinsider.com/lexington-biosciences-lxgtf-lnb-engages-clinical-research-organization/?utm_medium=Social&utm_source=TSI_Social_Link&utm_campaign=TSI_Social_1130